Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $2.1 million.

  • Kymera Therapeutics' Depreciation & Amortization (CF) rose 815.3% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 3171.9%. This contributed to the annual value of $7.4 million for FY2024, which is 10681.63% up from last year.
  • Per Kymera Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $2.1 million for Q3 2025, which was up 815.3% from $2.1 million recorded in Q2 2025.
  • Kymera Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $2.1 million during Q3 2025, with a 5-year trough of $485000.0 in Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $1.2 million, with a median of $891000.0 in 2023.
  • As far as peak fluctuations go, Kymera Therapeutics' Depreciation & Amortization (CF) skyrocketed by 12300.79% in 2024, and later surged by 753.35% in 2025.
  • Kymera Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $689000.0 in 2021, then grew by 18.72% to $818000.0 in 2022, then grew by 8.92% to $891000.0 in 2023, then soared by 123.01% to $2.0 million in 2024, then increased by 8.15% to $2.1 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.0 million for Q1 2025.